Granules India is a vertically integrated pharmaceutical company, headquartered in Hyderabad, India. We manufacture Active Pharmaceutical Ingredients APIs, Pharmaceutical Formulation Intermediates PFIs and Finished Dosages FDs, distributed to quality conscious customers in both regulated and semi-regulated markets. We are dedicated to excellence in manufacturing, quality and customer service.

Bayer Corporation and its related entities have agreed to pay USD 40 million to resolve alleged violations of the False Claims Act in connection with the drugs Trasylol, Avelox and Baycol.

The settlement announced yesterday arose from two whistleblower lawsuits filed and pursued by Laurie Simpson, a former employee of Bayer who worked in its marketing department. 

The U.S. Food and Drug Administration is the first regulatory authority to approve spesolimab as a treatment option for generalized pustular psoriasis (GPP) flares in adults, Boehringer Ingelheim announced today.

Spesolimab, marketed in the U.S. as SPEVIGO, is a novel, selective antibody that blocks the activation of the interleukin-36 receptor (IL-36R), a signaling pathway within the immune system shown to be involved in the pathogenesis of GPP.

Amneal Pharmaceuticals has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for IPX203, a novel, oral formulation of carbidopa/levodopa (CD/LD) extended-release capsules for the treatment of Parkinsons disease (PD).

IPX203 is a novel, oral formulation of CD/LD extended-release capsules designed for the treatment of Parkinson’s disease.

Zydus Lifesciences has received final approval from the United States Food and Drug Administration (USFDA) to market Venlafaxine Extended-Release Tablets and Pregabalin Extended-Release Tablets.

USFDA has approved Venlafaxine Extended-Release Tablets, USP 37.5 mg, 75 mg, 150 mg and 225 mg Extended-Release (ER) Tablets and Pregabalin ER Tablets, USP 82.5 mg, 165 mg and 330 mg which is generic of Lyrica CR.

​Breakthrough discovery made by University of British Columbia scientists by developing an oral insulin tablet which will work as replacement for daily insulin injections.

Research from Indian roots and currently involved in research at  University of British Columbia Dr. Anubhav Pratap Singh’s team developed a different kind of tablet that isn’t made for swallowing, but instead mouth-dissolving which dissolves when placed between the gum and cheek.

Indian Institute of Technology Tirupati is an autonomous engineering and technology education institute located in Tirupati, Andra Pradesh. It started functioning from 5 August 2015 in a temporary campus housed at Krishna Theja Educational Institutions in Chadalawada Nagar.

Post : Pharmacist

District Health Society, Zilla Panchayat Office, Health Branch, Surendranagar under the NHM program under 11 months contract basis and then on temporary basis to fill the following various cadre posts, also for future vacant posts.

Post : Pharmacist (RBSK)

No of Posts : 18
Age Limit : 40 years

CDFD, an autonomous institute of the Department of Biotechnology, Ministry of Science and Technology, invites applications from Indian nationals for the following purely temporary vacancy in research project titled “Characterization of tumor suppressor function of mRNA 4466” funded by CSIR. CDFD wishes to fill up the following post in the above project.

Post : Senior Research Fellow

Karnataka State Minerals Corporation Limited (KSMCL) has been a dynamic player in the Mining field and has been responsible for the efficient harnessing of these resources.  KSMCL has been involved in the Mining Business since 1966 and today is a recognized name in the industry with high competent and scientific methods to its credit. Capitalizing on this natural resource of Karnataka and acting as an agent of the Government has made KSMCL a vital link in the Local as well as Global trade relations.

Ajanta Pharma Limited, a specialty Pharmaceutical company engaged in development, manufacture and marketing of quality finished dosage in domestic and international markets is looking for suitable candidates for its formulation facility at Guwahati, Assam.

Dolutegravir-based antiretroviral therapies (ART) for HIV-1 are more effective for pregnant people than some other ART regimens commonly used in the U.S. and Europe, according to a study led by Harvard T.H. Chan School of Public Health researchers.

A new study from Washington University School of Medicine in St. Louis suggests a simple blood test administered before CAR-T cell treatment is initiated may identify which patients are predisposed to developing neurotoxic side effects after CAR-T cell therapy. Severe side effects can include seizures, brain swelling and strokes. Evidence of a stroke (red arrows) is seen on this MRI scan of the brain of a patient who developed neurotoxic side effects after CAR-T cell therapy.

Biological E. Limited (BE)'s 14-valent paediatric vaccine (investigational pneumococcal polysaccharide conjugate vaccine PCV14) is approved by the Subject Expert Committee of CDSCO  against S. pneumoniae infection in infants.

Streptococcus pneumoniae infection continues to be a leading cause of child mortality under 5 years of age in India and in developing countries. With the PCV14 vaccine, Biological E hopes to contribute to the prevention of invasive pneumococcal disease and protect millions of lives globally.

Cervavac was launched on September 1, 2022, after the Drugs Controller General of India had granted market authorization to Serum Institute of India. Cervavac is developed by a partnership of DBT and BIRAC with the Bill and Melinda Gates Foundation, supported by Serum Institute of India for the indigenous development of quadrivalent vaccines.

Dr Jitendra Singh said, this affordable and cost effective vaccine marks an important day for DBT and BIRAC as it takes India a step closer to PM Modi’s vision of Atmanirbhar Bharat.

Aurobindo Pharma to invest Rs. 300 crores for expanding its mammalian cell culture manufacturing facility of CuraTeQ Biologics which is a fully owned subsidiary of the Drug maker.

There was a meeting held on 1st september where all the board members agreed to expand its operations by establishing another mammalian cell culture manufacturing facility of higher capacity to cater to the future requirements. The capital expenditure for ramping up capacities is estimated to be around Rs.300 crores.

Novo Nordisk and Forma Therapeutics, Holdings Inc. announced that they have entered into a definitive agreement under which Novo Nordisk will acquire Forma Therapeutics for USD 20 per share in cash, which represents a total equity value of USD 1.1bn. Forma Therapeutics is a clinical-stage biopharmaceutical company focused on transforming the lives of patients with sickle cell disease (SCD) and rare blood disorders.

Novo Nordisk has agreed to pay USD 6.3 million to resolve allegations that it violated the False Claims Act by selling items to the United States that were manufactured in non-designated countries.

The settlement resolves allegations that Novo Nordisk violated the Trade Agreements Act, which restricts the procurement of goods under certain government contracts to purchases from specific designated countries, by submitting false claims for payment for medical devices that were manufactured in non-designated countries.

Caring for the world, one person at a time has inspired and united the people of Johnson & Johnson for over 125 years. We embrace research and science - bringing creative ideas, products and services to advance the health and well-being of people. Every day, our more than 130,000 employees across the world are blending heart, science and ingenuity to profoundly change the trajectory of health for humanity.